Short-term Clinical Efficacy of DC-CIK Cell Biotherapy Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

ZHANG Xia

doi:10.3969/j.issn.1672-7185.2019.03.026

Abstract：Objective? To investigate the short-term clinical effect of DC-CIK cell biotherapy combined with conventional chemotherapy in the treatment of advanced non-small cell lung cancer. Methods A total of 86 patients with non-small cell lung cancer admitted to the Fifth People’s Hospital of Dalian from January 2014 to June 2015 were selected and divided into control group and observation group, 43 cases in each group according to different treatment regimen. The control group was treated with conventional chemotherapy, while the observation group was treated with DC-CIK cell biotherapy on the basis of conventional chemotherapy. The short-term clinical effects, serum tumor markers, immune function indexes and adverse reactions were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the observation group was 53.5%, and was significantly higher than 30.2% of the control group (χ2=4.778,P＜0.05). After treatment, the levels of TNF-a, CD4+, CD4+/CD8+ in the two groups were significantly improved, and the improvement degree in the observation group was significantly better than that of the control group (t=4.378, 5.095 and 4.336, P<0.05). The incidence of adverse reactions during treatment was 39.53% in the observation group and 34.88% in the control group. The incidence of adverse reactions in the observation group was slightly higher than that in the control group, but there was no significant difference (χ2=0.199, P>0.05). Conclusion DC-CIK cell biotherapy combined with conventional chemotherapy for non-small cell lung cancer has better short-term efficacy than chemotherapy alone. It can improve the immune level of patients without increasing adverse reactions and has better clinical application value.